Literature DB >> 25192741

BalestraWeb: efficient online evaluation of drug-target interactions.

Murat Can Cobanoglu1, Zoltán N Oltvai1, D Lansing Taylor1, Ivet Bahar2.   

Abstract

SUMMARY: BalestraWeb is an online server that allows users to instantly make predictions about the potential occurrence of interactions between any given drug-target pair, or predict the most likely interaction partners of any drug or target listed in the DrugBank. It also permits users to identify most similar drugs or most similar targets based on their interaction patterns. Outputs help to develop hypotheses about drug repurposing as well as potential side effects.
AVAILABILITY AND IMPLEMENTATION: BalestraWeb is accessible at http://balestra.csb.pitt.edu/. The tool is built using a probabilistic matrix factorization method and DrugBank v3, and the latent variable models are trained using the GraphLab collaborative filtering toolkit. The server is implemented using Python, Flask, NumPy and SciPy.
© The Author 2014. Published by Oxford University Press.

Entities:  

Mesh:

Year:  2014        PMID: 25192741      PMCID: PMC4271144          DOI: 10.1093/bioinformatics/btu599

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 INTRODUCTION

Contemporary drug discovery faces important challenges: bringing a new molecular entity to the market is estimated to cost upward of 1.8 billion US$ (Paul ), and the rate of new drug discovery has steadily halved every 9 years for the past 60 years (Scannell ). One of the common suggestions brought forth to explain and remedy this trend is a paradigm shift in drug discovery efforts from high-affinity binding on a single target toward modulation of cellular network states through multiple interactions (Csermely , 2013; Hopkins, 2008; Keskin ; Korcsmaros ; Mencher and Wang, 2005; Zimmermann ). The development of computational methods that can efficiently assess potential new interactions for drug repurposing thus became an important goal in quantitative systems/network pharmacology research. We recently introduced a probabilistic matrix factorization (PMF) method that can be applied to known drug–target interaction graphs for predicting new interactions (Cobanoglu ). Here, we introduce BalestraWeb, a Web server that has been developed for allowing users to efficiently obtain results from the PMF analysis, and assess the likelihood of interaction between any drug–target pair.

2 METHOD

BalestraWeb is built by training a latent factor model, as described in our previous work (Cobanoglu ), on approved drugs and their interactions data from DrugBank v3 (Knox ). To build the latent factor model, we use the GraphLab collaborative filtering toolkit implementation (Low ). We mapped all the known names, brand names and synonyms of the drugs and targets to the relevant latent factor using a pre-computed hash table that allows constant time access and enables maximal efficiency. The server allows users to submit three types of queries: drug–target interaction, drug–drug similarity and target–target similarity. In the former case (Fig. 1), the input is mapped to the corresponding drug latent vector (LV) and target LV, and the dot product of these vectors yields a score for the probabilistic occurrence of the queried drug–target interaction. Alternatively, the user can enter a single type of input, either a drug or a target. If a single drug is entered, the server retrieves the LV for that drug and screens it against the entire set of LVs corresponding to all targets, so as to identify known and newly predicted targets. Drug–drug and target–target similarity queries provide information on drugs (or targets) similar to the query drug (or target) based on the cosine similarity of their LVs.
Fig. 1.

BalestraWeb architecture and underlying methodology. The user input (lower left) is mapped onto the latent factor vector(s) u (for targets), learned by minimizing squared error regularized by Frobenius norm (see equation at top left). The output (right) contains a score R representative of predicted interaction confidence along with a graphical representation of the close neighborhood of the query drug (Sunitinib) and/or query target (SCN5A) in the drug-target association network, along with a table of known and predicted interactions. Similar features hold for drug-drug and target-target similarity searches and outputs

BalestraWeb architecture and underlying methodology. The user input (lower left) is mapped onto the latent factor vector(s) u (for targets), learned by minimizing squared error regularized by Frobenius norm (see equation at top left). The output (right) contains a score R representative of predicted interaction confidence along with a graphical representation of the close neighborhood of the query drug (Sunitinib) and/or query target (SCN5A) in the drug-target association network, along with a table of known and predicted interactions. Similar features hold for drug-drug and target-target similarity searches and outputs The output is an interactive graph (that can be downloaded in JSON format) and a table displaying both the known drug–target interactions for the query drug (target) and the top N predicted targets (drugs), rank-ordered by their score. Users can select to view a second layer of interactions beyond the immediate neighbors of the query drug/target in the bipartite network of drugs and targets. The resulting subnet of interactions thus provides a more complete picture of the investigated drug/target in the context of the interactions of their known targets/drugs. In addition to providing information on the distribution of scores in general in the tutorial, we provide query-specific histograms in the output files: the distribution of the predicted confidence score (for each member of the drug–target pairs) or the histogram of cosine similarities (for each member of the drug–drug or target–target pairs). These histograms facilitate the interpretation of the specific score released for the query pair in the context of the complete distribution of scores for the investigated drug/target, and help make a better assessment of the significance of the outputted score.

3 DISTINCTIVE FEATURES

There are three important distinguishing features of BalestraWeb: its ability to provide information on the likelihood of interaction between any drug and any target; its reliance on interaction profiles instead of chemical similarity; and its ability to compare drugs with drugs and targets with targets. The widely used similarity ensemble approach (SEA) (Keiser ) uses ligand similarity to identify new ligands based on chemical similarity. STITCH (Kuhn ) is an extensive repository of protein and chemicals (1.07 billion interactions), including predictions based on chemical similarities of compounds. However, the interactions predicted by BalestraWeb are not based on a particular chemical or genomic similarity method, but on the assessment of comparable interaction patterns, and as such they differ from, or complement, those predicted by SEA or listed by STITCH.

4 CONCLUSION

BalestraWeb provides users the ability to predict the most likely interaction partners of any drug or target beyond those known and compiled in the DrugBank. The technology used to build the Web server scales linearly with the number of drugs or targets and is therefore easily scalable to larger datasets as they become available. Our plan is to regularly update the underlying engine and optimized parameters by using the newly released data. The modular architecture of the software allows us to update the Web server to reflect changes as new data become available. Free, fast and easy-to-use BalestraWeb enables researchers to help eliminate improbable drug–target interactions and efficiently focus their limited resources on selected drugs. Funding: Support from the NIH (U19 AI068021 and PO1 DK096990) is gratefully acknowledged by I.B. Conflict of interest: none declared.
  12 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 3.  The efficiency of multi-target drugs: the network approach might help drug design.

Authors:  Péter Csermely; Vilmos Agoston; Sándor Pongor
Journal:  Trends Pharmacol Sci       Date:  2005-04       Impact factor: 14.819

Review 4.  Multi-target therapeutics: when the whole is greater than the sum of the parts.

Authors:  Grant R Zimmermann; Joseph Lehár; Curtis T Keith
Journal:  Drug Discov Today       Date:  2006-11-28       Impact factor: 7.851

Review 5.  Towards drugs targeting multiple proteins in a systems biology approach.

Authors:  O Keskin; A Gursoy; B Ma; R Nussinov
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 6.  Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.

Authors:  Peter Csermely; Tamás Korcsmáros; Huba J M Kiss; Gábor London; Ruth Nussinov
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  Relating protein pharmacology by ligand chemistry.

Authors:  Michael J Keiser; Bryan L Roth; Blaine N Armbruster; Paul Ernsberger; John J Irwin; Brian K Shoichet
Journal:  Nat Biotechnol       Date:  2007-02       Impact factor: 54.908

8.  DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.

Authors:  Craig Knox; Vivian Law; Timothy Jewison; Philip Liu; Son Ly; Alex Frolkis; Allison Pon; Kelly Banco; Christine Mak; Vanessa Neveu; Yannick Djoumbou; Roman Eisner; An Chi Guo; David S Wishart
Journal:  Nucleic Acids Res       Date:  2010-11-08       Impact factor: 16.971

Review 9.  Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).

Authors:  Simon K Mencher; Long G Wang
Journal:  BMC Clin Pharmacol       Date:  2005-04-26

10.  STITCH 4: integration of protein-chemical interactions with user data.

Authors:  Michael Kuhn; Damian Szklarczyk; Sune Pletscher-Frankild; Thomas H Blicher; Christian von Mering; Lars J Jensen; Peer Bork
Journal:  Nucleic Acids Res       Date:  2013-11-28       Impact factor: 16.971

View more
  9 in total

1.  Opportunities for drug repositioning from phenome-wide association studies.

Authors:  Majid Rastegar-Mojarad; Zhan Ye; Jill M Kolesar; Scott J Hebbring; Simon M Lin
Journal:  Nat Biotechnol       Date:  2015-04       Impact factor: 54.908

2.  Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.

Authors:  D Lansing Taylor; Albert Gough; Mark E Schurdak; Lawrence Vernetti; Chakra S Chennubhotla; Daniel Lefever; Fen Pei; James R Faeder; Timothy R Lezon; Andrew M Stern; Ivet Bahar
Journal:  Handb Exp Pharmacol       Date:  2019

3.  A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.

Authors:  Andrew M Stern; Mark E Schurdak; Ivet Bahar; Jeremy M Berg; D Lansing Taylor
Journal:  J Biomol Screen       Date:  2016-03-08

4.  Computational Methods for Drug Repurposing.

Authors:  Rosaria Valentina Rapicavoli; Salvatore Alaimo; Alfredo Ferro; Alfredo Pulvirenti
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding.

Authors:  Mary Hongying Cheng; Ethan Block; Feizhuo Hu; Murat Can Cobanoglu; Alexander Sorkin; Ivet Bahar
Journal:  Front Neurol       Date:  2015-06-09       Impact factor: 4.003

6.  Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology.

Authors:  Fen Pei; Hongchun Li; Mark J Henderson; Steven A Titus; Ajit Jadhav; Anton Simeonov; Murat Can Cobanoglu; Seyed H Mousavi; Tongying Shun; Lee McDermott; Prema Iyer; Michael Fioravanti; Diane Carlisle; Robert M Friedlander; Ivet Bahar; D Lansing Taylor; Timothy R Lezon; Andrew M Stern; Mark E Schurdak
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

7.  Mechanisms of Action of Autophagy Modulators Dissected by Quantitative Systems Pharmacology Analysis.

Authors:  Qingya Shi; Fen Pei; Gary A Silverman; Stephen C Pak; David H Perlmutter; Bing Liu; Ivet Bahar
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

8.  Web-based 3D-visualization of the DrugBank chemical space.

Authors:  Mahendra Awale; Jean-Louis Reymond
Journal:  J Cheminform       Date:  2016-05-04       Impact factor: 5.514

Review 9.  Bioengineering tools for the production of pharmaceuticals: current perspective and future outlook.

Authors:  Surendra Sarsaiya; Jingshan Shi; Jishuang Chen
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.